MYCN and neoplasm: We sought to validate our ALK immunoassays using both neuroblastoma cell lines and tumor tissue from the Th‐ALKF1174L/MYCN transgenic model, which has previously demonstrated the inadequacy of the first‐generation ALK inhibitor, crizotinib, to elicit therapeutic responses in ALK F1174L‐driven neuroblastomas (Berry et al., 2012).